Pharming Group N.V. balance sheet

At the end of fiscal 2025, Pharming Group N.V. had total assets of $500m and shareholders' equity of $277m. It held $145m in cash against $98.1m of debt: net cash of $47.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pharming Group N.V.: balance sheet, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	74	205	192	207	62	55	145
Receivables	29	36	30	28	46	55	55
Inventory	16	21	27	42	57	56	65
Total current assets	119	263	249	278	316	278	299
Total assets	256	418	397	426	463	400	500
Total current liabilities	114	77	47	60	78	74	116
Short-term debt	0	2	2	2	2	4	5
Long-term debt	0	150	139	132	137	78	93
Total debt	0	152	141	133	138	82	98
Shareholders' equity	117	183	193	205	219	221	277
Net debt (negative = net cash)	−74	−53	−51	−74	77	27	−47
Shares outstanding	63m	64m	65m	66m	67m	68m	70m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: PHAR vs SVA MNKD vs PHAR MGTX vs PHAR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Pharming Group N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pharming Group N.V.